Previous studies have reported that high P4HB expression is significantly related to the poor prognosis of BC patients,inhibition of P4HB improve the sensibility of BC cells to Gemcitabine by activating apoptosis and the PERK/eIF2α/ATF4/CHOP pathways [27]. Here, EIF2A is linked to breast cancer.